The European Medicines Agency (EMA) on Thursday identified severe allergic reactions as possible side effects of Novavax Inc.’s Covid-19 vaccine.
–
250 thousand doses of the Novavax covid vaccineNuvaxovid, have been administered in Europe so far since its launch in December, according to the European Center for Disease Prevention and Control.
–
The EMA announced that it would also update the product information for the vaccine to add unusual or decreased skin sensation as a new secondary effect.
–
–
The United States Food and Drug Administration (FDA) authorized this Wednesday the use of the Covid-19 vaccine of Novavax, in people over 21 years of age.
–
The US Centers for Disease Control and Prevention (CDC) still need to approve the use of the vaccine before it can be made available to inoculate people.
–
It is anticipated that a CDC advisory panel on vaccines meets on Tuesday, but the agenda has not yet been released.
–
Novavax shares rose 1.3% to $70.89 after its two dose antigen became the fourth Covid vaccine authorized for use in adults in the United States. (Rts)
—
